News briefs: Rituximab biosimilar; Watson to change name; Baxter Brazil plans ... The Pharma Letter The Sandoz follicular lymphoma Phase III clinical trial for biosimilar monoclonal antibody rituximab, a biosimilar of Roche's Rituxan/MabThera (which generated sales of over $5 billion in the first three quarters of this year; The Pharma Letter October ... |
